Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 5,818 shares, a growth of 652.7% from the June 30th total of 773 shares. Based on an average daily trading volume, of 5,883 shares, the short-interest ratio is presently 1.0 days.
Sunshine Biopharma Stock Down 4.1%
Shares of Sunshine Biopharma stock opened at $0.06 on Friday. The firm’s 50 day moving average price is $0.06 and its 200-day moving average price is $0.11. Sunshine Biopharma has a 52-week low of $0.02 and a 52-week high of $0.65.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
See Also
- Five stocks we like better than Sunshine Biopharma
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
